Hydrocodone Combination Up-scheduling Marches Forward Despite FDA Ambivalence
This article was originally published in The Pink Sheet Daily
FDA’s Drug Safety and Risk Management Advisory Committee votes 19-10 to move the opioid drugs to the more restrictive Schedule II because their abuse potential is similar to other drugs already that already have the controlled substances designation.
You may also be interested in...
DEA reschedules hydrocodone combination products from Schedule III to Schedule II with 45-day effective date; industry had requested more time to implement handling requirements.
FDA draft guidance says there is no clear epidemiologic strategy for gathering the data to demonstrate that has reduced abuse; the agency outlines four possible kinds of abuse deterrence claims, three of which can be obtained through pre-market studies.
FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.